[1] Baptiste DC,Fehlings MG.Pharmacological approaches to repair the injured spinal cord[J]. J Neurotrauma, 2006, 23(3/4): 318-334. [2] Kubeck JP, Merola A, Mathur S, et al.End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model[J]. Spine (Phila Pa 1976), 2006, 31(3): 257-261. [3] Carelli S, Marfia G, Di Giulio AM, et al.Erythropoietin: recent developments in the treatment of spinal cord injury[J]. Neurol Res Int, 2011: 453179. [4] Mofidi A, Bader A, Pavlica S.The use of erythropoietin and its derivatives to treat spinal cord injury[J]. Mini Rev Med Chem, 2011, 11(9): 763-770. [5] 顾兵,金建波,李华南,等. 大鼠创伤性脊髓损伤模型的建立[J]. 中国临床药理学与治疗学, 2011, 16(7): 721-728. [6] 顾兵,王俊,李华南,等. 大剂量甲强龙冲击治疗大鼠脊髓挫伤的形态学研究[J]. 中国药理学通报, 2012, 28(10): 1417-1423. [7] Oyinbo CA.Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade[J]. Acta Neurobiol Exp (Wars), 2011, 71(2): 281-299. [8] Tehranipour M,Moghimi A.Neuroprotective effects of testosterone on regenerating spinal cord motoneurons in rats[J]. J Motor Behav, 2010, 42(3): 151-155. [9] Joyeux-Faure M.Cellular protection by erythropoietin: new therapeutic implications[J] ? J Pharmacol Exp Ther, 2007, 323(3): 759-762. [10] Grasso G, Sfacteria A, Cerami A, et al.Erythropoietin as a tissue- protective cytokine in brain injury: what do we know and where do we go[J]? Neuroscientist, 2004, 10(2): 93-98. [11] Basso DM, Beattie MS, Bresnahan JC.MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability[J]. J Neurotrauma, 1996, 13(7): 343-359. [12] Vitellaro-Zuccarello L, Mazzetti S, Madaschi L, et al.Chronic erythropoietin-mediated effects on the expression of astrocyte markers in a rat model of contusive spinal cord injury[J]. Neuroscience, 2008, 151(2): 452-466. [13] Sirén AL, Fasshauer T, Bartels C, et al.Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system[J]. Neurotherapeutics, 2009, 6(1): 108-127. [14] Chang CM, Lee MH, Wang TC, et al.Brain protection by methylprednisolone in rats with spinal cord injury[J]. NeuroReport, 2009, 20(10): 968-972. [15] Sakurai M, Hayashi T, Abe K, et al.Delayed and selective motor neuron death after transient spinal cord ischemia a role of apoptosis[J]? J Thorac Cardiovasc Surg, 1998, 115(6): 1310-1135. [16] Smith PD, Puskas F, Fullerton DA, et al.Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin[J]. J Thorac Cardiovasc Surg, 2011, 141(1): 256-260. [17] Ning B, Zhang A, Song H, et al.Recombinant human erythropoietin prevents motor neuron apoptosis in a rat model of cervical sub-acute spinal cord compression[J]. Neurosci Lett, 2011, 490(1): 57-62. [18] Cetin A, Nas K, Büyükbayram H, et al.The effects of systemically administered methylprednisolone and recombinant human erythropoietin after acute spinal cord compressive injury in rats[J]. Eur Spine J, 2006, 15(10): 1539-1544. [19] McDonald JW,Belegu V. Demyelination and remyelination after spinal cord injury[J]. J Neurotrauma, 2006, 23(3/4): 345-359. [20] Nashmi R,Jones OT,Fehlings MG.Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2 K+ channels after chronic spinal cord injury[J]. Eur J Neurosci, 2000, 12(2): 491-506. [21] Pinzon A, Marcillo A, Quintana A, et al.A reassessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model[J]. Brain Res, 2008, 1243: 146-151. [22] Okutan O, Solaroglu I, Beskonakli E, et al.Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats[J]. J Clin Neurosci, 2007, 14(4) : 364-368. [23] Savino C, Pedotti R, Baggi F, et al.Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis[J]. J Neuroimmunol, 2006, 172(1/2) : 27-37. |